AtriCure Q3 revenue $134.3M (+15.8% YoY); net loss narrows to $0.3M; raises FY2025 outlook

AtriCure, Inc.

2025-Q3 EPS reported -$0.28 revenue$394,028,000

Revenue $134.3M, +15.8% YoY (+15.1% constant currency); US $109.3M (+14.5%), intl $25.0M (+22.0%).
Net loss $0.3M vs $7.9M loss in Q3 2024; GAAP EPS loss $0.01 vs $0.17; adjusted EBITDA $17.8M (+$9.9M).
Generated $30.1M cash in Q3, $25.1M YTD; raised full-year 2025 financial outlook.
Key product drivers: AtriClip FLEX-Mini, EnCompass clamp, cryoSPHERE MAX probe for pain management.
Gross margin 75.5%, up 59 bps YoY on favorable product mix.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.